Fig 1.
Proposed development scheme and anticipated costs for Cryptosporidium drug development.
Abbreviations: pharmacokinetic (PK), 50% inhibitory concentration (IC50), selectivity index (SI, defined as IC50host cell line/IC50Cryptosporidium), and compound (cmpd). a. Screening: US$2–US$5 per compound; b. IC50s: US$100 per compound; c. Hit prioritization and mouse PK: US$5,000 per compound; d. Mouse: US$10K–US$20K/compound, Calves: US$50K/compound, Gnotobiotic piglet: US$200K/compound; e. Medicinal chemistry: US$500K/year x 3 years; f. Good laboratory practice (GLP) Toxicology Studies: US$1.65M; g. Human challenge: US$400K/compound.
Table 1.
Proposed target product profile for treatments for diarrhea due to cryptosporidiosis.
Table 2.
Key needs to accelerate Cryptosporidium drug development.